The search to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer is at the foundation of a new, cross-sector collaboration. Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach; the Cancer Center at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, and the Pancreatic Cancer Research Team managed by Cancer Research And Biostatistics announced today they will work together to eradicate the disease.
from The Medical News http://ift.tt/1apFMsP
from The Medical News http://ift.tt/1apFMsP
No comments:
Post a Comment